ELV vs. INCY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ELV and INCY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ELV | INCY |
|---|---|---|
| Company Name | Elevance Health, Inc. | Incyte Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 75.14 billion USD | 20.60 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | October 30, 2001 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ELV and INCY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| 5-Day Price Return | 7.26% | -1.73% |
| 13-Week Price Return | 5.25% | 19.82% |
| 26-Week Price Return | -13.20% | 71.27% |
| 52-Week Price Return | -20.70% | 29.41% |
| Month-to-Date Return | 2.72% | 11.41% |
| Year-to-Date Return | -11.68% | 50.79% |
| 10-Day Avg. Volume | 1.54M | 2.75M |
| 3-Month Avg. Volume | 2.23M | 1.98M |
| 3-Month Volatility | 29.80% | 28.34% |
| Beta | 0.52 | 0.80 |
Profitability
Return on Equity (TTM)
ELV
12.91%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
ELV’s Return on Equity of 12.91% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
INCY
29.83%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 29.83% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
ELV
2.84%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
ELV’s Net Profit Margin of 2.84% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
INCY
24.69%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 24.69% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ELV
4.35%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
ELV’s Operating Profit Margin of 4.35% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
INCY
30.76%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 30.76% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Return on Equity (TTM) | 12.91% | 29.83% |
| Return on Assets (TTM) | 4.60% | 20.37% |
| Net Profit Margin (TTM) | 2.84% | 24.69% |
| Operating Profit Margin (TTM) | 4.35% | 30.76% |
| Gross Profit Margin (TTM) | -- | 93.47% |
Financial Strength
Current Ratio (MRQ)
ELV
0.23
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
ELV’s Current Ratio of 0.23 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
INCY
3.20
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
INCY’s Current Ratio of 3.20 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ELV
0.73
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
ELV’s Debt-to-Equity Ratio of 0.73 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
INCY
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ELV
7.67
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
ELV’s Interest Coverage Ratio of 7.67 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Current Ratio (MRQ) | 0.23 | 3.20 |
| Quick Ratio (MRQ) | 0.23 | 2.86 |
| Debt-to-Equity Ratio (MRQ) | 0.73 | 0.01 |
| Interest Coverage Ratio (TTM) | 7.67 | 6.86 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ELV
2.11%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
ELV’s Dividend Yield of 2.11% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ELV
27.56%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
ELV’s Dividend Payout Ratio of 27.56% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Dividend Yield (TTM) | 2.11% | 0.00% |
| Dividend Payout Ratio (TTM) | 27.56% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ELV
13.09
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
In the lower quartile for the Health Care Providers & Services industry, ELV’s P/E Ratio of 13.09 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
INCY
17.49
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
INCY’s P/E Ratio of 17.49 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ELV
0.37
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
ELV’s P/S Ratio of 0.37 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
INCY
4.32
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 4.32 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
ELV
1.66
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
ELV’s P/B Ratio of 1.66 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
INCY
3.56
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
INCY’s P/B Ratio of 3.56 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ELV | INCY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.09 | 17.49 |
| Price-to-Sales Ratio (TTM) | 0.37 | 4.32 |
| Price-to-Book Ratio (MRQ) | 1.66 | 3.56 |
| Price-to-Free Cash Flow Ratio (TTM) | 19.46 | 17.37 |